Repare Therapeutics (NASDAQ:RPTX) Stock Price Up 7.6%

Repare Therapeutics Inc. (NASDAQ:RPTX)’s stock price rose 7.6% during trading on Thursday . The stock traded as high as $21.60 and last traded at $21.54. Approximately 5,608 shares traded hands during trading, a decline of 96% from the average daily volume of 159,757 shares. The stock had previously closed at $20.01.

RPTX has been the subject of several research reports. Zacks Investment Research cut shares of Repare Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday. Guggenheim initiated coverage on shares of Repare Therapeutics in a research report on Monday, June 28th. They issued a “buy” rating and a $46.00 price objective for the company. HC Wainwright initiated coverage on shares of Repare Therapeutics in a research report on Monday, September 13th. They issued a “buy” rating and a $54.00 price objective for the company. Morgan Stanley boosted their price objective on shares of Repare Therapeutics from $45.00 to $47.00 and gave the company an “overweight” rating in a research report on Monday, August 16th. Finally, Bloom Burton initiated coverage on shares of Repare Therapeutics in a research report on Thursday, September 30th. They issued a “buy” rating and a $49.00 price objective for the company. One analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $47.57.

The firm’s 50-day moving average price is $30.37 and its two-hundred day moving average price is $31.83. The stock has a market cap of $802.47 million, a PE ratio of -10.30 and a beta of -0.35.

Repare Therapeutics (NASDAQ:RPTX) last announced its quarterly earnings results on Thursday, August 12th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.10). The firm had revenue of $0.28 million for the quarter. As a group, research analysts forecast that Repare Therapeutics Inc. will post -2.6 EPS for the current year.

In other Repare Therapeutics news, Director David P. Bonita sold 887 shares of the company’s stock in a transaction that occurred on Tuesday, September 7th. The shares were sold at an average price of $33.93, for a total transaction of $30,095.91. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Orbimed Advisors Llc sold 7,082 shares of the company’s stock in a transaction that occurred on Wednesday, August 25th. The shares were sold at an average price of $34.34, for a total transaction of $243,195.88. The disclosure for this sale can be found here. Insiders have sold 66,416 shares of company stock valued at $2,261,782 in the last three months. 33.60% of the stock is currently owned by corporate insiders.

Several hedge funds have recently modified their holdings of RPTX. Price T Rowe Associates Inc. MD lifted its holdings in shares of Repare Therapeutics by 2,044.2% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,176,004 shares of the company’s stock valued at $36,668,000 after buying an additional 1,121,157 shares during the period. BVF Inc. IL raised its holdings in shares of Repare Therapeutics by 25.2% during the first quarter. BVF Inc. IL now owns 3,722,398 shares of the company’s stock valued at $114,240,000 after acquiring an additional 750,207 shares during the last quarter. ARK Investment Management LLC raised its holdings in shares of Repare Therapeutics by 113.8% during the first quarter. ARK Investment Management LLC now owns 1,358,589 shares of the company’s stock valued at $41,695,000 after acquiring an additional 723,196 shares during the last quarter. Great Point Partners LLC acquired a new position in shares of Repare Therapeutics during the second quarter valued at approximately $13,597,000. Finally, Logos Global Management LP raised its holdings in shares of Repare Therapeutics by 33.0% during the first quarter. Logos Global Management LP now owns 900,000 shares of the company’s stock valued at $27,621,000 after acquiring an additional 223,106 shares during the last quarter. 71.52% of the stock is owned by institutional investors and hedge funds.

About Repare Therapeutics (NASDAQ:RPTX)

Repare Therapeutics Inc, a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair.

Featured Article: What is Net Asset Value (NAV)?

Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.